Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
LaunchBridgeBio Oncology Therapeutics Publishes Preclinical Data on First-in-Class BBO-8520 Molecule for KRASG12C Mutant Tumors.
Dec 09, 2024
South San FranciscoBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma
Product Description
BridgeBio Oncology Therapeutics has announced the publication of preclinical data supporting BBO-8520, a direct dual inhibitor that targets both ‘ON’ and ‘OFF’ forms of KRASG12C, indicating significant therapeutic potential.
Company Information
Company
BridgeBio Oncology Therapeutics
Location
South San Francisco, California, United States
About
BridgeBio Oncology Therapeutics, a clinical-stage biopharmaceutical company, focuses on RAS-pathway malignancies, specifically developing therapies for patients with KRASG12C mutations. Their lead candidate, BBO-8520, is a first-in-class dual inhibitor targeting both active and inactive forms of KRASG12C, demonstrating significant preclinical efficacy. The company aims to overcome adaptive resistance seen in traditional therapies. Their recent publication highlights the innovative mechanism of action and potential clinical benefits of BBO-8520.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment BridgeBio Oncology Therapeutics ships something new, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
South San FranciscoBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma